****

**Routing Sheet – PRMC Full Review (not Cooperative Studies)**

**Study Title:**

**Principal Investigator:**

**Phase: NA / I / II / III / IV**

**Study Coordinator(s):**

**Sub-Investigators:**

**Gene Therapy Study:** Yes **/** No

**Chart Review/Biospecimen Study:** Yes **/** No

**Study Funded:** Yes **/** No **Source:**

|  |  |  |
| --- | --- | --- |
| **Length of Accrual Period:** |  | **years** |
| **Total Study Accrual Goal:** |  | **(all sites)**  |
| **Local patient population meeting criteria:** |  | **(per year)** |
| **Estimated local patient accrual per year:** |  | **(per year)** |

|  |  |
| --- | --- |
| **IND Status (if applicable):** |  |
| **Holder:** |  |
| **Applicant:** |  |

|  |  |
| --- | --- |
| **Study Drug(s):** |  |
| **Mechanism of action:** |  |
| **What is the hypothesis being tested?** |  |

**Prioritization**

The PI should score this section as described in each category below. Protocols that are approved for Scientific Merit will be rated as **high** or **low** priority based on the Prioritization score and general discussion from the committee.

|  |  |
| --- | --- |
| **Category/Criteria** | Score |
| **Does the study compete with PI-initiated studies?** YES NO |  |
| **The study includes Institutional Translational Research.** YES=1, NO=0 |  |
| **The study provides care that does not exist at the Institution.** YES=1, NO=0 |  |
| **The study enhances referrals of patients.** YES=1, NO=0 |  |
| **Patient accrual: Expected total number of patients enrolled per trial:**Score 3 = at least 2 patients in Phase I or Phase II trialScore 3 = more than 20 patients in Phase III trialScore 2 = 5 to 19 patients in Phase III or Phase IV trialScore 1 = less than 5 patients in Phase III or Phase IV trial |  |
| **Cancer Center Scientific Mission: (Please check one or more; and Score 0, 1, 2, 3 as noted below)** [ ]  Cancer Immunology/Immunotherapy, Tolerance, Inflammation [ ]  Molecular Oncology and Biomarkers [ ]  Signaling and Angiogenesis [ ]  Cancer Prevention and ControlScore 1 = the study involves at least one of these areasScore 2 = there is potential for collaboration or development of additional research studies from the trial (**Name of Collaborator: ; Nature of Collaboration:**  )Score 3 = the study specifically uses a product or strategy that is an existing strength at our institutionScore 3 = there is a defined collaboration or additional research from the trial already included in the proposal  |  |
| **The study enhances the reputation of the Georgia Cancer Center.** YES=1, NO=0 |  |
| **The study enhances the reputation of the PI.**1. Publication YES=1, NO=0
2. Grant application YES=1, NO=0
 |  |
| **The study enhances the PI’s and/or Institution’s relationship with the sponsor.** YES=1, NO=0 |  |
| **Total Score** | **/13** |

**Please provide a justification to open the study at GCC/AU (e.g., reason to open, programmatic strategy, good use of available time and monetary resources).**

**Additional Comments:**

**PI Signature: Date:**